Literature DB >> 12010798

Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations.

Michael Kalafatis1, Paolo Simioni, Daniela Tormene, Daniel O Beck, Sonia Luni, Antonio Girolami.   

Abstract

A 44-year-old woman with a history of severe thrombotic manifestations presented with a markedly reduced activated protein C-sensitivity ratio (APC-SR). DNA sequencing of and around the regions encoding the APC cleavage sites in the factor Va molecule excluded the presence of the factor VLeiden mutation and of other known genetic mutations. No antiphospholipid antibodies were present in the patient's plasma and both prothrombin time and activated partial thromboplastin time were normal. The total immunoglobulin fraction was isolated from the patient's plasma and found to induce severe APC resistance when added to normal plasma and to factor V-deficient plasma supplemented with increasing concentrations of factor V. Immunoblotting and immunoprecipitation experiments with the total immunoglobulin fraction purified from the patient's plasma demonstrated that the antibody recognizes factor V, is polyclonal, and has conformational epitopes on the entire factor V molecule (heavy and light chains, and B region). Thus, the immunoglobulin fraction interferes with the anticoagulant pathway involving factor V. The inhibitor was isolated by sequential affinity chromatography on protein G-Sepharose and factor V-Sepharose. The isolated immunoglobulin fraction inhibited factor Va inactivation by APC because of impaired cleavage at Arg306 and Arg506 of the heavy chain of the cofactor. The isolated immunoglobulin fraction was also found to inhibit the cofactor effect of factor V for the inactivation of factor VIII by the APC/protein S complex. Our data provide for the first time the demonstration of an antifactor V antibody not related to the presence of antiphospholipid antibodies, which is responsible for thrombotic rather than hemorrhagic symptoms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010798     DOI: 10.1182/blood.v99.11.3985

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis.

Authors:  Hina Ogawa; Masayoshi Souri; Kazunori Kanouchi; Tsukasa Osaki; Rie Ohkubo; Tomoko Kawanishi; Sachiko Wakai; Keita Morikane; Akitada Ichinose
Journal:  Int J Hematol       Date:  2018-11-16       Impact factor: 2.490

Review 3.  Soft materials to treat central nervous system injuries: evaluation of the suitability of non-mammalian fibrin gels.

Authors:  Raivo Uibo; Ivo Laidmäe; Evelyn S Sawyer; Lisa A Flanagan; Penelope C Georges; Jessamine P Winer; Paul A Janmey
Journal:  Biochim Biophys Acta       Date:  2009-01-22

4.  Autoimmune Factor V Deficiency That Took 16 Years to Diagnose due to Pseudodeficiency of Multiple Coagulation Factors.

Authors:  Takaaki Kato; Takaya Hanawa; Mea Asou; Tomohiko Asakawa; Hisashi Sakamaki; Makoto Araki
Journal:  Case Rep Med       Date:  2021-01-12

5.  Acquired factor V inhibitor in a patient with mantle cell lymphoma presenting with hematuria followed by thrombosis: a case report.

Authors:  Naif I Aljohani; John H Matthews
Journal:  Int Med Case Rep J       Date:  2014-02-24

6.  Acquired factor V deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor V inhibitor: a case report and review of the literature.

Authors:  Xiangyu Wang; Xuemei Qin; Yuan Yu; Ran Wang; Xinguang Liu; Min Ji; Minran Zhou; Chunyan Chen
Journal:  Blood Coagul Fibrinolysis       Date:  2017-06       Impact factor: 1.276

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.